直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

European IP Blog

Double Patenting Is Grounds for Refusal Against European Patent Applications Says EPO in G4/19

July 1, 2021

Authored and Edited by Matthew Havron; Maeve O'Flynn

Last week, the Enlarged Board of Appeal (EBA) confirmed in G4/19 that a European patent application can be refused for ‘double patenting’ despite the absence of an explicit double patenting provision in the European Patent Convention.

Double patenting, as a concept, seeks to prevent applicants from obtaining multiple patents in the same jurisdiction claiming the same subject-matter. In addition to the administrative inefficiencies such practices would place on the European Patent Office (EPO), allowing double patenting could tempt abuse of royalty arrangements or other matters relating to the licensing/transfer of rights for a particular invention to the detriment of third parties. In recognition of this concept, the EPO will usually issue an objection where a claim has identical scope to that of a previous granted claim covering the same territories. However, because the European Patent Convention (EPC) does not explicitly refer to double patenting, it has been unclear as to whether a European patent application can actually be refused on the ground of double patenting.

The question of double patenting was therefore referred to the EBA to determine whether, and under what provision, an application could be refused due to double patenting. The EBA has now confirmed that the EPO can rely upon Article 125 EPC as the basis to refuse applications for unallowable double patenting, which specifies that:

In the absence of procedural provisions in this Convention, the European Patent Office shall take into account the principles of procedural law generally recognised in the Contracting States.

In its decision, the EBA held that double patenting was a principle of procedural law within the meaning of this provision, and thus Article 125 EPC provides the source for the prohibition on double patenting. The EBA additionally held that the above did not depend on the relative filing dates of the two European patent applications, but instead deemed that i) two EP applications filed on the same day, ii) a divisional application and its parent, and iii) a later EP application claiming priority to an earlier EP application should all be treated the same in this regard.

As a result of the decision, examiners at the EPO now have the mandate to refuse an EP patent application according to one of scenarios i) - iii) on the grounds of double patenting using Article 125 EPC. The most affected practice impacted by the decision appears to concern scenario iii), in which an identical EP application (EP2) is re-filed within the priority year of an original EP patent application (EP1) in order to extend the term of protection by up to one year. In light of the decision, applicants will need to decide between rapid enforceability and patent term, as the EPO will only allow one European patent application for the claimed invention to proceed to grant (either EP1 or EP2).

Since the decision only concerns multiple EP applications, applicants still have the option of filing one or more national (priority) applications for a claimed invention, followed by an EP (or PCT(EP)) application claiming priority from the national application(s) in order to benefit from an extra year of patent term for the claimed invention. The national application(s) can be accelerated for rapid enforceability, while the EP application extends the term of protection for the claimed invention. However, many countries exclude protection of an invention by both a European patent and a national patent having the same effective date. In most cases, this leads to the European patent superseding the national patent on grant (see NatLaw table X, col.1).

While the EBA has provided further clarity in relation to the area of double patenting, the EBA did not take the opportunity to address the requirements behind the terms “same invention” and “same applicant”. For instance, it remains unclear how different a claim must be to no longer be directed to the “same invention”. Will a claim that differs merely by virtue of the wording relating to one feature be considered as directed to the “same invention”? Concerning the latter point, patent law dictates that two different applicants who each file a patent application on the same day for the same invention can each proceed to obtain a patent as if the other application did not exist. Accordingly, it remains unclear whether the double patenting prohibitions as outlined by the EBA are avoided by assigning one of the cases to a different applicant prior to grant?

The undefined terms mentioned above will likely lead to issuance of further decisions from the EPO on the matter of double patenting in the future.

Tags

Obviousness-type Double Patenting (OTDP), European Patent Office (EPO), referral to enlarged board of appeal, patent term extension

Related Offices

London

Contacts

Maeve O'Flynn
Partner
London
+44 (0)20 7864 2856
Email

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP